{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:06Z","timestamp":1791357246699,"version":"4.3.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822c1636","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:58:34Z","timestamp":1317758314000},"page":"613-624","source":"Crossref","is-referenced-by-count":60,"title":["Antipsychotics, Antidepressants, Anticonvulsants, and Placebo on the Symptom Dimensions of Borderline Personality Disorder"],"prefix":"10.1097","volume":"31","author":[{"given":"Antonio","family":"Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/appi.ajp.2009.09020263","article-title":"Borderline personality disorder.","volume":"166","author":"Kernberg","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1176\/ajp.155.12.1733","article-title":"Axis I comorbidity of borderline personality disorder.","volume":"155","author":"Zanarini","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1360-0443.2008.02413.x","article-title":"New onset of substance abuse disorders in borderline personality disorder over 7 years of follow-up: findings from the Collaborative Longitudinal Personality Disorders Study.","volume":"104","author":"Walter","year":"2009","journal-title":"Addiction"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.163.1.20","article-title":"Borderline personality disorder and suicidality.","volume":"163","author":"Oldham","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1176\/appi.ajp.158.2.295","article-title":"Treatment utilization by patients with personality disorders.","volume":"158","author":"Bender","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/comp.2001.19749","article-title":"Treatment histories of borderline inpatients.","volume":"42","author":"Zanarini","year":"2001","journal-title":"Compr Psychiatry"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1176\/appi.ajp.160.2.274","article-title":"The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.","volume":"160","author":"Zanarini","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-004-0041-9","article-title":"Update on pharmacotherapy of borderline personality disorder.","volume":"6","author":"Zanarini","year":"2004","journal-title":"Curr Psychiatry Rep"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)16770-6","article-title":"Borderline personality disorder.","volume":"364","author":"Lieb","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"R12-12-20210128","first-page":"CD005653","article-title":"Pharmacological interventions for people with borderline personality disorder.","author":"Binks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.yic.0000224784.90911.66","article-title":"Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials.","volume":"21","author":"Nose","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.","volume":"8","author":"Herpertz","year":"2007","journal-title":"World J Biol Psychiatry"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1521\/pedi.2009.23.2.156","article-title":"Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms.","volume":"23","author":"Mercer","year":"2009","journal-title":"J Pers Disord"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.","volume":"196","author":"Lieb","year":"2010","journal-title":"Br J Psychiatry"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.08r04526gre","article-title":"Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials.","volume":"71","author":"Ingenhoven","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results.","volume":"59","author":"Furokawa","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder.","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.v69n0412","article-title":"Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.","volume":"69","author":"Pascual","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.","volume":"193","author":"Schulz","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.","volume":"163","author":"Nickel","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.","volume":"45","author":"Cowdry","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v62n0311","article-title":"A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.","volume":"62","author":"Hollander","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R28-12-20210128","first-page":"270","article-title":"A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.","volume":"24","author":"Reich","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4088\/JCP.v65n1112","article-title":"Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.","volume":"65","author":"Nickel","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","article-title":"Treatment of aggression with topiramate in male borderline patients. A double-blind, placebo-controlled study.","volume":"57","author":"Nickel","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study.","volume":"19","author":"Tritt","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.","volume":"54","author":"Coccaro","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","article-title":"SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with BPD.","volume":"159","author":"Rinne","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4088\/JCP.v65n0314","article-title":"Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder.","volume":"65","author":"Simpson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004714-199502000-00005","article-title":"Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.","volume":"15","author":"Salzman","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1986.01800070081010","article-title":"Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.","volume":"43","author":"Soloff","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder.","volume":"50","author":"Soloff","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.","volume":"162","author":"Soler","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.npp.1300153","article-title":"Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4088\/JCP.v63n0511","article-title":"Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.","volume":"63","author":"Frankenburg","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder.","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R42-12-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo.","volume":"43","author":"Goldberg","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R43-12-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.","volume":"62","author":"Zanarini","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4088\/JCP.v69n0617","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.","volume":"69","author":"Linehan","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R45-12-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0924-977X(94)90296-8","article-title":"A trial of carbamazepine in borderline personality disorder.","volume":"4","author":"de la Fuente","year":"1994","journal-title":"Eur Neuropsychopharmacol"},{"key":"R46-12-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study.","volume":"26","author":"Loew","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R47-12-20210128","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.v67n0705","article-title":"Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study.","volume":"67","author":"Bellino","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R48-12-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.v59n0302","article-title":"Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.","volume":"59","author":"Benedetti","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R49-12-20210128","first-page":"535","article-title":"Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder.","volume":"25","author":"Teicher","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"R50-12-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCP.0b013e318166c4bf","article-title":"Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.","volume":"28","author":"Van den Eynde","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R51-12-20210128","first-page":"506","article-title":"An open trial of valproate in borderline personality disorder.","volume":"56","author":"Stein","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"R52-12-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4088\/JCP.v59n1206","article-title":"Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.","volume":"59","author":"Kavoussi","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R53-12-20210128","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4088\/JCP.v66n0904","article-title":"Oxcarbazepine in the treatment of borderline personality disorder: a pilot study.","volume":"66","author":"Bellino","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R54-12-20210128","first-page":"113","article-title":"The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.","volume":"20","author":"Kutcher","year":"1995","journal-title":"J Psychiatry Neurosci"},{"key":"R55-12-20210128","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0006-3223(99)00128-6","article-title":"Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.","volume":"46","author":"Schulz","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R56-12-20210128","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4088\/JCP.v66n1013","article-title":"Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as a target.","volume":"66","author":"Villeneuve","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R57-12-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10401230802467545","article-title":"Quetiapine in patients with borderline personality disorder: an open-label trial.","volume":"20","author":"Adityanjee","year":"2008","journal-title":"Ann Clin Psychiatry"},{"key":"R58-12-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-2008-1076730","article-title":"Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial.","volume":"41","author":"Roepke","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"R59-12-20210128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.psychres.2007.07.006","article-title":"Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.","volume":"161","author":"Bellino","year":"2008","journal-title":"Psychiatry Res"},{"key":"R60-12-20210128","first-page":"403","article-title":"Treatment of borderline personality disorder with olanzapine.","volume":"9","author":"Shoja-Shafti","year":"2006","journal-title":"Arch Iranian Med"},{"key":"R61-12-20210128","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0010-440X(93)90065-C","article-title":"Clozapine treatment of borderline personality disorder: a preliminary study.","volume":"34","author":"Frankenburg","year":"1993","journal-title":"Compr Psychiatry"},{"key":"R62-12-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.pnpbp.2006.08.012","article-title":"Quetiapine for the treatment of borderline personality disorder; an open-label study.","volume":"31","author":"Perrella","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R63-12-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4088\/JCP.v63n0311","article-title":"Treatment of borderline personality disorder with risperidone.","volume":"63","author":"Rocca","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R64-12-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4088\/JCP.v60n0710","article-title":"Clozapine reduces severe self mutilation and aggression in psychotic patients with borderline personality disorder.","volume":"60","author":"Chengappa","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R65-12-20210128","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0269881108095715","article-title":"Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.","volume":"24","author":"Bellino","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R66-12-20210128","first-page":"137","article-title":"An open trial of sertraline in borderline personality disordered patients with impulsive aggression.","volume":"55","author":"Kavoussi","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R67-12-20210128","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1176\/ajp.148.8.1064","article-title":"Fluoxetine in the treatment of borderline and schizotypal personality disorders.","volume":"148","author":"Markowitz","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R68-12-20210128","first-page":"773","article-title":"Venlafaxine in the treatment of borderline personality disorders.","volume":"31","author":"Markowitz","year":"1995","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"R69-12-20210128","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201110000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:17:01Z","timestamp":1618035421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201110000-00012"}},"subtitle":["A Meta-Analysis of Randomized Controlled and Open-Label Trials"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822c1636","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}